GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aurora Spine Corp (OTCPK:ASAPF) » Definitions » LT-Debt-to-Total-Asset

ASAPF (Aurora Spine) LT-Debt-to-Total-Asset : 0.28 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Aurora Spine LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aurora Spine's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.28.

Aurora Spine's long-term debt to total assets ratio declined from Sep. 2023 (0.31) to Sep. 2024 (0.28). It may suggest that Aurora Spine is progressively becoming less dependent on debt to grow their business.


Aurora Spine LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aurora Spine's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurora Spine LT-Debt-to-Total-Asset Chart

Aurora Spine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.32 0.22 0.27 0.29

Aurora Spine Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.29 0.28 0.29 0.28

Aurora Spine LT-Debt-to-Total-Asset Calculation

Aurora Spine's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=3.415/11.985
=0.28

Aurora Spine's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=3.416/12.092
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurora Spine  (OTCPK:ASAPF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Aurora Spine LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aurora Spine's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurora Spine Business Description

Traded in Other Exchanges
Address
20 Holly Street, Suite 300, Toronto, ON, CAN, M4S 3B1
Aurora Spine Corp is engaged in the business of the development and commercialization of minimally invasive interspinous fusion systems and devices. The product portfolio includes implants, surgical tools, and biologics. It derives revenues primarily from the sale of spinal surgery implants, consumable products used in spinal surgeries, and service revenue for referring products to its customers.